immune system
|
• tamoxifen-treated mice exhibit progressive degeneration and lesions of the knee articular cartilage from 2-6 months of age
• lesions exhibit as either empty lacuna or confined loss of cartilage tissue
• 3 month old tamoxifen-treated mice show an early osteoarthritis-like phenotype, including loss of proteoglycan content and cartilage tissue and increased number of hypertrophic chondrocytes in articular cartilage
• 6 month old tamoxifen-treated mice exhibit more severe destruction of the articular cartilage, associated with greater loss of proteoglycan content and cartilage, osteophyte formation and increased subchondral bone mass
|
skeleton
|
• tamoxifen-treated mice exhibit increased articular chondrocyte apoptosis
|
|
• tamoxifen-treated mice exhibit progressive degeneration and lesions of the knee articular cartilage from 2-6 months of age
• lesions exhibit as either empty lacuna or confined loss of cartilage tissue
• 3 month old tamoxifen-treated mice show an early osteoarthritis-like phenotype, including loss of proteoglycan content and cartilage tissue and increased number of hypertrophic chondrocytes in articular cartilage
• 6 month old tamoxifen-treated mice exhibit more severe destruction of the articular cartilage, associated with greater loss of proteoglycan content and cartilage, osteophyte formation and increased subchondral bone mass
|
osteophytes
(
J:271724
)
|
• osteophyte formation is seen in 6 month old tamoxifen-treated mice
|
|
• tamoxifen-treated mice exhibit synovial hyperplasia
|
|
• tamoxifen-treated mice show increased articular cartilage thickness at 2 months of age with zonal disruption and loss of proteoglycan content
|
cellular
|
• tamoxifen-treated mice exhibit increased articular chondrocyte apoptosis
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| osteoarthritis | DOID:8398 | J:271724 | ||


Analysis Tools